Back to Search
Start Over
Assessment of RNA Interference Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Companies by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio
- Source :
- M2 Presswire. January 9, 2024
- Publication Year :
- 2024
-
Abstract
- M2 PRESSWIRE-January 9, 2024-: Assessment of RNA Interference Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Companies by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio (C)1994-2024 [...]
- Subjects :
- bluebird bio, Inc. -- Product development
Alnylam Pharmaceuticals Inc. -- Product development
Pfizer Inc. -- Product development
Medical research -- Reports
Medicine, Experimental -- Reports
Business -- Research
Biotechnology industry -- Product development
RNA -- Reports
Clinical trials -- Reports
Pharmaceutical industry -- Product development
Business
Business, international
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 Presswire
- Publication Type :
- News
- Accession number :
- edsgcl.778793721